Clinical trials: Patients With Diabetes.
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
OPL-0401-201 is a multicenter study to investigate the safety and efficacy of OPL-0401 in patients with diabetes mellitus (DM) with diabetic retinopathy.
- Trial name
- NCT05393284
- Testing
- OPL-0401 Dose 1
- Where
- 25 sites in United States
- Volunteers
- 114 people
- Sponsor
- Valo Health, Inc.
Diabetes Mellitus, Type 2
A Study of LY3493269 in Participants With Type 2 Diabetes
The main purpose of this study is to determine the side effects related to LY3493269 in participants with type 2 diabetes. Blood tests will be performed to check concentrations of LY3493269 in the bloodstream.
- Trial name
- NCT04515576
- Testing
- LY3493269, Dulaglutide
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Evaluation of an Ascensia Diabetes Care Blood Glucose Meter and App System
The purpose of this study is to assess the utility of the Contour Diabetes App 2.0 when used with the Contour Next One meter (the Onyx system).
- Trial name
- NCT03165110
- Testing
- Onyx BG Meter / App System
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Ascensia Diabetes Care
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without metformin over a period of 24 weeks of treatment…
- Trial name
- GETGOAL-L (NCT00715624)
- Testing
- Lixisenatide (AVE0010), Basal Insulin, Metformin
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 496 people
- Sponsor
- Sanofi
Diabetes Mellitus
Glucose Meter Study
The purpose of this study is to evaluate if the meal marker and reminder feature of the Contour meter along with education maintains or increases frequency of testing blood sugar after meals and enables behavioral changes that…
- Trial name
- NCT00782496
- Testing
- Education + new meter, Education + new meter + feature activation
- Where
- 4 sites in United States
- Volunteers
- 211 people
- Sponsor
- Ascensia Diabetes Care
Type 2 Diabetes Mellitus
Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs
Primary Objective: To evaluate the safety of Gla-300 in insulin naïve T2D participants uncontrolled on oral antihyperglycemic drugs Secondary Objective: To assess the efficacy of Gla-300 on glycemic control in insulin naïve T2D…
- Trial name
- SAFEGUARD (NCT04980027)
- Testing
- Insulin glargine (U300)
- Where
- 2 sites in India
- Volunteers
- 228 people
- Sponsor
- Sanofi
Type 2 Diabetes
Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes
Determine the effect of treatment with INCB019602 administered as an add-on to stable dose metformin therapy in type 2 diabetic subjects on safety and glycemic control.
- Trial name
- NCT00698789
- Testing
- INCB019602, Metformin
- Where
- 22 sites in United States
- Volunteers
- 48 people
- Sponsor
- Incyte Corporation
Diabetes Mellitus, Type 2
A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes
This study looks into how the type 2 diabetes medicine, semaglutide, can prevent risk of heart disease complications and stroke.
- Trial name
- NCT04032197
- Testing
- Semaglutide
- Where
- 4 sites in Austria, Denmark and 1 more
- Volunteers
- 101 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. This is a 28-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, in…
- Trial name
- NCT00138580
- Testing
- vildagliptin
- Where
- United States
- Volunteers
- 345 people
- Sponsor
- Novartis
Diabetes Mellitus Type 2
A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin
This 5 arm study will evaluate the efficacy and safety of RO5093151 and RO5027838 in patients with type 2 diabetes mellitus on a stable dose of metformin.
- Trial name
- NCT00823680
- Testing
- RO5027838, RO5093151
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 1
Feasibility Study of the Effect of Intra-Dermal Insulin Injection on Blood Glucose Levels After Eating
This study is to determine the effect of intra-dermal (ID) administration of regular and of rapid-acting insulin, before eating, on blood glucose levels for several hours after a standard meal (a mixed, liquid meal).
- Trial name
- NCT00553488
- Testing
- Regular insulin (Humulin), Insulin lispro (Humalog)
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Becton, Dickinson and Company
Glucose Lowering
To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients
To assess the pharmacokinetics of AZD1656, and its metabolite, in type 2 diabetes mellitus patients with varying degrees of renal impairment and to compare the results with those in patients with normal renal function.
- Trial name
- NCT01069926
- Testing
- AZD1656
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Study of REGN1193 in Patients With Type 2 Diabetes Mellitus
This is a phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of REGN1193 in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT02284425
- Testing
- REGN1193
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- Regeneron Pharmaceuticals
Efficacy, Safety
Combination of Ertugliflozin And Sitagliptin Efficacy, Safety & Tolerability (CEASE Diabetes) Study
Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study to evaluate the efficacy, safety and tolerability of Ertugliflozin and Sitagliptin Con-initiation in patients with Type II…
- Conditions
- Efficacy, Safety, Tolerability
- Trial name
- CEASE (NCT05556291)
- Testing
- Combinations of Oral Blood Glucose Lowering Drugs
- Where
- 3 sites in Pakistan
- Volunteers
- 190 people
- Sponsor
- Getz Pharma
Type 1 Diabetes Mellitus
A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics
This is a two-period study of participants with type 1 diabetes mellitus (T1DM). In each period, participants will receive once daily injections of stable dose LY2605541 or insulin glargine for 28 to 35 days followed by…
- Trial name
- NCT01925989
- Testing
- LY2605541, Insulin Glargine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
The purpose of this study is to observe clinical effectiveness of canagliflozin by mean haemoglobin A1c (HbA1C) and body weight changes from baseline to 12 weeks in Indian type 2 diabetes participants.
- Trial name
- NCT03604224
- Testing
- Canagliflozin 300 mg
- Where
- 3 sites in India
- Volunteers
- 178 people
- Sponsor
- Johnson & Johnson Private Limited
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes.
- Trial name
- NCT03311724
- Testing
- Tirzepatide
- Where
- 13 sites in United States
- Volunteers
- 111 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus Type 2
Hypoglycemia- and Weight-related Quality of Life in Patients With Diabetes Mellitus Type 2 on Sulfonylurea Derivatives.
1. A prospective, non-interventional study, 125 patients with Diabetes Mellitus Type2 will be enrolled, who, while on metformin, have a sub-optimal glycemic control and who thus will receive additional treatment with a…
- Trial name
- NCT01244646
- Where
- 22 sites in Netherlands
- Volunteers
- 48 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)
This study will compare the effects of 2.0 mg exenatide once weekly injection as monotherapy to 3 active comparators(metformin, dipeptidyl peptidase-4 inhibitor, and thiazolidinedione) in drug naive patients with type 2 diabetes…
- Trial name
- NCT00676338
- Testing
- exenatide once weekly, metformin, sitagliptin
- Where
- 106 sites in United States, Argentina and 20 more
- Volunteers
- 820 people
- Sponsor
- AstraZeneca
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.